ipamorelin/cjc1295 CJC‑1295 & Ipamorelin Therapy CJC-1295 (Mod GRF 1-29) &

In STEP 1, participants without diabetes who received semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% with placebo

Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, and Stampfer MJ (1998)

[50][51] Such changes indicate that regular GHRT with Sermorelin can resist changes in body composition underlying sarcopenia and frailty that lead to loss of independence

Firstly the Review was based on research papers that were very suspect and involved groups of individuals that did not represent a wide cross section of society (the primary study was of mainly elderly males)

I felt completely at ease and so comfortable in her capable hands